Olema Pharmaceuticals, Inc (OLMA)

Olema Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies for women's cancers. OP-1250, an estrogen receptor antagonist and a selective ER degrader, is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.